Human gene variant linked to chronic inflammation in older mice
An experiment in 14- to 16-month-old mice linked a human gene variant to weaker repair-related responses two weeks after chemotherapy.
Our read
Mechanisms- Studied:
- Experiments in older mice carrying human APOE variants, 2 weeks, against APOE3 mice
- What changed:
- APOE4 mice had higher blood levels of inflammatory signals than APOE3 mice before chemotherapy
- The catch:
- Follow-up lasted only 2 weeks, limiting assessment of long-term inflammation
Editor of record: Boris Djordjevic · AgingResearch.News
Fourteen- to 16-month-old C57Bl/6 mice carrying human APOE3 or APOE4, versions of a gene involved in handling fats, underwent an animal experiment with two chemotherapy combinations. Researchers compared measurements before treatment and two weeks afterward. Mice received doxorubicin plus either docetaxel or cyclophosphamide.
Before treatment, APOE4 mice had higher blood levels of three inflammatory signals than APOE3 mice. Several signals fell after chemotherapy in APOE4 mice. No significant APOE3-specific changes appeared. Brain gene-activity mapping suggested increased activity in pathways related to nerve-cell connections, inflammation and fat metabolism in the APOE3 hippocampus, a memory-related region. These pathways were suppressed in APOE4 mice. The authors concluded that older APOE4 mice had chronic body-wide inflammation and compromised repair-associated responses after chemotherapy, suggesting vulnerability to treatment-related brain toxicity.
Why it matters
Cognitive impairment after chemotherapy raises the question of how inherited differences may shape the aging brain’s response to cancer treatment.
Caveats
Molecular responses are not measures of cognitive function, and these results came from mice. The abstract does not give group sizes or chemotherapy doses.
- Doxorubicin + cyclophosphamide
- Doxorubicin + docetaxel
- Inflammation
- APOE
- Postchemotherapy cognitive impairment
- Mice
The paper
Qatar University; Georgetown University
The American Journal of Pathology, Jun 10, 2026, Open access
Comments
Be the first to comment.